RNS Number : 9728VAlliance Pharma PLC12 April 2023

12 April 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Annual Report & Accounts and Notice of AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the following documents are now available on the Group's website, www.alliancepharmaceuticals.com:

·      The Annual Report & Accounts for the year ended 31 December 2022

·      The Notice of the 2023 Annual General Meeting ("AGM"), which will be held at 09.00 am on 25th May 2023.

Printed copies of both documents have been mailed to those shareholders who have opted out of receiving electronic communications from the Group.

Printed copies of the documents are also available by contacting Buchanan by email at [email protected] or by telephoning Buchanan on 020 7466 5000.

For further information:

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

[email protected]




Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff


[email protected]




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith


Corporate Broking: James Black




Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Broking: Patrick Robb


About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDMSCITMPTMTABMMJ



Supplied Euroland.com - Privacy Policy